As clinical trials become increasingly complex, many sponsors struggle with fragmented systems, disconnected workflows, and limited visibility across trial operations. This whitepaper explores how greater connectivity between IRT/RTSM, eCOA, and clinical supply functions can help reduce operational friction, improve oversight, strengthen supply continuity, and support a better experience for sites and participants.
eTMF Evaluation Checklist
Redefining Site Feasibility: A Call for Clarity and Collaboration
Clinical trial operations are approaching a decisive turning point. As AI experimentation accelerates, the industry faces a widening divide between organizations equipped with digitally connected workflows and those still dependent on paper, email, and fragmented systems. This year’s landscape reveals five strategic imperatives that define how sites, sponsors, and CROs can adapt to a rapidly evolving operational reality.
How Sponsors Can Ensure Their Sites Are Aligned with ICH E6 R3
The Advantages of Conducting Early-Phase Clinical Research in Canada
Master Protocols-including platform, umbrella, and basket trials-offer significant benefits and efficiencies in drug development compared with traditional trial protocols. However, their perpetual nature, adaptive designs, and evolving requirements make randomisation inherently more complex. As a result, implementing and maintaining robust randomisation for Master Protocols can be challenging for sponsors. Selecting the right IRT provider is therefore critical. This paper outlines five essential questions sponsors should ask when evaluating IRT providers for Master Protocols, with a focus on long-term trial success, regulatory readiness, and operational resilience.
As emerging biopharmas race to integrate Artificial Intelligence into their clinical pipelines, many make the costly mistake of retrofitting AI onto slow, legacy EDC systems. Watch this expert panel to learn how modern, AI-native clinical data platforms automate data reconciliation, accelerate study builds, and future-proof your Phase II/III trials.
Is your eCOA UAT stuck in time? Inadequate temporal validation causes massive delays in pivotal biotech trials. Learn how AI-driven automation and modern eClinical platforms solve the "UAT time conundrum," allowing sponsors to confidently launch complex, time-sensitive protocols in weeks, not months.
See how Gameto, a biotechnology company focused on redefining women's health, leveraged Castor’s EDC and decentralized capabilities to successfully launch their global studies in just 3 weeks. Discover how a lean biotech team scaled their research rapidly across multiple international sites.
When evaluating eCOA vendors, the license fee is just the tip of the iceberg. This brief examines the true Total Cost of Ownership (TCO) for eCOA in clinical trials, revealing the hidden operational, integration, and service costs that hit biotech sponsors and how natively integrated platforms prevent budget overruns.
In this case study, discover how Parexel takes on the most operationally complex prostate cancer trials — delivering with confidence, speed, and control to de-risk pivotal programs, accelerate momentum, and help critical innovations reach patients faster.
A high-level, visual overview of ClinSphere® Trial IntelX™, highlighting what it is and what makes it different. The infographic presents Trial IntelX™ as an AI-powered predictive intelligence platform that uses WCG’s extensive benchmarked trial and protocol dataset to optimize clinical trial design before launch. It emphasizes key data assets (80,000+ protocols, 40,000+ trials, 125+ operational metrics) and positions the solution as a tool to reduce burden, improve enrollment, and support better site selection.
An in-depth thought leadership whitepaper explaining how sponsors can operationalize the FDA’s 2025 guidance on inclusive and representative clinical trial design. It outlines current industry challenges (e.g., restrictive eligibility criteria, participant burden, placement uncertainty), summarizes the FDA’s updated expectations, and demonstrates how ClinSphere® Trial IntelX™ enables data-driven protocol design, burden reduction, optimized site selection, and realistic subgroup planning to align with regulatory requirements from the start.
A concise, sales-focused product overview designed for commercial conversations. It clearly outlines the core capabilities of Trial IntelX™ predictive enrollment forecasting, participant and site burden scoring, country and site intelligence, protocol simulation, and portfolio optimization. The sell sheet positions Trial IntelX™ as a solution that helps sponsors “see their trial before it starts,” reduce costly amendments, shorten start-up timelines, and improve overall execution quality.
Welcome to PurpleLab – Learn how we help accelerate clinical trials
AI is driving evidence-based asset, program and study decisions
AI is driving evidence-based asset, program and study decisions
Innovating with Generative and agentic AI to drive efficiency and quality in clinical trials
Enhance predictability and quality in design, planning and trial delivery by leveraging novel tools and approaches
Discussion of opportunities on the ethical and regulatory challenges regarding artificial intelligence in clinical trials. The episode is focused through the lens of the IRB review, and how a multi-stakeholder task force led by the Multi-Regional Clinical Trials (MRCT) Center of Brigham and Women’s Hospital and WCG will address the growing need for guidance in this rapidly evolving area of research.
Institutional Review Boards (IRBs) are critical in the oversight of clinical research and the protection of participants, and with the right expertise, ethical review can result in more efficient, higher quality, more consistent research outcomes. With managing highly complex trials and navigating the changing regulatory landscape, it is increasingly crucial for research professionals to partner with an expert IRB partner.
Early adoption of WCG ClinSphere® eReview Manager provides insight into how a centralized, digital review infrastructure can improve efficiency and transparency across the IRB submission lifecycle. Initial performance data and operational experience indicate measurable gains, including reduced submission entry time, faster review cycles, and significant reductions in document handling effort.
The transition from preclinical to clinical testing is a pivotal moment in drug development. It’s also one of the most challenging development milestones, beset by unknown risks, unexpected data, and potential regulatory hurdles to overcome. In this article, Quotient Sciences experts discuss how proper planning can avoid missteps in first-in-human studies, looking at trial design, CMC, and regulatory considerations.
Quotient Sciences is dedicated to Phase I trials and early drug development, providing the insights you need by offering comprehensive clinical pharmacology services for all Phase I study programs. Our services encompass expert clinical study design, thorough data analysis, and detailed reporting. With our fully integrated approach, we ensure seamless execution and deliver high-quality results safely and quickly.
Partnering with an experienced first-in-human specialist such as Quotient Sciences is the key to navigating early development with confidence. Through our work with small molecules and biologics, we provide the expertise, infrastructure, and agility needed to move your novel therapy forward, faster.
Dr. Andreas Reichl, Senior Drug Development Consultant, and Dr. Kevin Schaab, Senior Drug Development Consultant, both from Quotient Sciences, present a practical breakdown of how early-phase experts design programs to mitigate risks and efficiently move novel molecules into PoC assessments.